Initiates Make-or-Break Phase 3 Clinical Trials in AngelMan Syndrome
Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company developing novel therapeutics for rare neurological disorders, announced the launch of a crucial phase 3 clinical trial in Angelman Syndrome named NEPTUNE. OV101, its lead candidate for the treatment of syndrome and Fragile X Syndrome is a delta-selective...
